We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.87%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.54B
AUM Growth
+$55.8M
Cap. Flow
-$1.48B
Cap. Flow %
-15.48%
Top 10 Hldgs %
82.65%
Holding
142
New
10
Increased
13
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$28.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.1M
3
MRUS
Merus
MRUS
+$9.82M
4
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$6.94M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.88M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$274M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
3
OMER icon
Omeros
OMER
+$11.5M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.52M
5
IMGN
Immunogen Inc
IMGN
+$9.01M

Sector Composition

Rank Sector Weight
1 Healthcare 80.73%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
101
DELISTED
Dynavax Technologies
DVAX
$1.09M 0.01%
75,000
– –
TENX icon
102
Tenax Therapeutics
TENX
$399M
$1.07M 0.01%
13
– –
SCYX icon
103
SCYNEXIS
SCYX
$36.5M
$1.01M 0.01%
+5,845
New +$1.65M
AFMD
104
DELISTED
Affimed
AFMD
$992K 0.01%
40,000
– –
XLRN
105
DELISTED
Acceleron Pharma
XLRN
$977K 0.01%
28,765
– –
PTN
106
Palatin Technologies
PTN
$14.1M
$905K 0.01%
1,640
– –
ADAP
107
DELISTED
Adaptimmune Therapeutics
ADAP
$815K 0.01%
100,000
– –
ALDX icon
108
Aldeyra Therapeutics
ALDX
$95.3M
$808K 0.01%
142,000
– –
FPRX
109
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$796K 0.01%
19,247
– –
ALNY icon
110
Alnylam Pharmaceuticals
ALNY
$38.2B
$629K 0.01%
11,340
– –
ABUS icon
111
Arbutus Biopharma
ABUS
$849M
$628K 0.01%
180,582
– –
AIXC
112
AIxCrypto Holdings Inc
AIXC
$13.4M
$612K 0.01%
3
– –
MDGL icon
113
Madrigal Pharmaceuticals
MDGL
$12.5B
$526K 0.01%
+57,764
New +$693K
BDSI
114
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$496K 0.01%
210,021
– –
WINT
115
DELISTED
Windtree Therapeutics Inc
WINT
$492K 0.01%
254,973
– –
CMRX
116
DELISTED
Chimerix, Inc.
CMRX
$453K ﹤0.01%
115,216
– –
SRRA
117
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$398K ﹤0.01%
5,000
– –
FMI
118
DELISTED
Foundation Medicine, Inc.
FMI
$390K ﹤0.01%
20,892
– –
AKAO
119
DELISTED
Achaogen Inc
AKAO
$379K ﹤0.01%
100,000
– –
CCXI
120
DELISTED
ChemoCentryx, Inc.
CCXI
$220K ﹤0.01%
49,064
– –
LJPC
121
DELISTED
La Jolla Pharmaceutical Company
LJPC
$220K ﹤0.01%
13,746
– –
BGMSP
122
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$83K ﹤0.01%
13,253
– –
BTX.WS
123
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$9K ﹤0.01%
20,084
– –
IOVA icon
124
Iovance Biotherapeutics
IOVA
$2.08B
– –
-1,066,285
Closed -$5.42M
IRWD icon
125
Ironwood Pharmaceuticals
IRWD
$598M
– –
-201,981
Closed -$1.85M
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Baker Bros. Advisors held 142 positions worth $9.54B, up 0.59% from $9.48B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors withdrew a net $1.48B in Q2 2016, closing 7 positions and reducing 15 holdings. Its most notable exit was ANACOR PHARMACEUTICALS INC COM, an estimated $274M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 77% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Intellia Therapeutics worth $22.7M.

  • Baker Bros. Advisors's largest Q2 2016 buy was Intellia Therapeutics: 1,062,120 shares worth $22.7M.
  • Baker Bros. Advisors added most to Acadia Pharmaceuticals in Q2 2016, an estimated $10.1M increase.
  • Baker Bros. Advisors's biggest Q2 2016 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $15.9M.
  • Baker Bros. Advisors fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $274M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $9.54B portfolio in Q2 2016.
  • Baker Bros. Advisors opened 10 new positions and closed 7 in Q2 2016.
  • Baker Bros. Advisors's portfolio value rose 0.59% quarter-over-quarter to $9.54B.

Based on Baker Bros. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.